Metindol retard, 75 mg 25 pcs

Methindol retard has anti-inflammatory, analgesic, antipyretic, desensitizing effect.

Blocks cyclooxygenase in arachidonic acid cascade, inhibits GH biosynthesis.

Indications

Active ingredient

Composition

Active ingredient:

Indomethacin 75 mg.

Associates:

Cellulose microcrystalline,

Potato starch,

Methacrylic acid copolymer,

Talc,

Magnesium stearate.

How to take, the dosage

Methindol retard is taken orally, without chewing, during or immediately after a meal, with plenty of water or milk.

Adults: 1 or 2 tablets per day, depending on the severity of the disease and individual sensitivity. Do not exceed the dose of more than 150 mg per day.

Interaction

Enhances plasma concentrations of digoxin, methotrexate and lithium drugs, which may increase their toxicity.

Ethanol, colchicine, GCS and corticotropin increase the risk of GI bleeding.

It increases hypoglycemic effect of insulin and oral hypoglycemic drugs; it increases the effect of indirect anticoagulants, antiaggregants, thrombolytics (alteplase, streptokinase and urokinase) – the risk of bleeding.

Decreases the effect of diuretics; with potassium-saving diuretics the risk of hyperkalemia increases; decreases the effectiveness of uricosuric and hypotensive drugs (including beta-adrenoblockers); increases the side effects of glucocorticosteroids, acetylsalicylic acid, estrogen, etc. NSAIDS.

Cyclosporine and gold drugs increase nephrotoxicity (probably due to inhibition of prostaglandin synthesis in kidneys).

Cefamandol , cefaperazone, cefotetan, valproic acid, plikamycin increase the incidence of hypoprothrombinemia and the risk of bleeding.

Antacids and colestyramine reduce absorption of indomethacin.

Accelerates zidovudine toxicity (due to inhibition of metabolism); in infants, increases the risk of toxic effects of aminoglycosides (because it reduces renal clearance and increases blood concentrations).

Concomitant use with serotonin reuptake inhibitors increases the risk of GI bleeding.

Myelotoxic drugs increase manifestations of hematotoxicity of the drug.

The combined use with paracetamol increases the risk of nephrotoxic effects.

Special Instructions

During treatment, monitoring of peripheral blood counts and functional status of the liver and kidneys is necessary.

If it is necessary to determine 17-ketosteroids, the drug should be discontinued 48 hours before the study.

Antacids should be used to prevent and reduce dyspeptic phenomena.

Impact on driving and operating machinery During treatment, caution must be exercised when driving motor vehicles and engaging in other potentially dangerous activities that require increased concentration and quick psychomotor reactions.

Contraindications

Side effects

Overdose

Symptoms: nausea, vomiting, severe headache, dizziness, memory problems and disorientation. In more severe cases paresthesias, numbness of extremities and seizures are observed.

Treatment: is rapid elimination of the drug from the body and application of appropriate symptomatic drugs. Indomethacin cannot be eliminated from the body by hemodialysis.

Similarities